Brainstorm Cell Therapeutics Inc. (BCLI)
R&D Expense Growth
26.48%
Quarterly · Period ending:
BCLI R&D Expense Growth
Latest reported26.48%period ending
Latest reported26.48%period ending
BCLI Quarterly R&D Growth (QoQ) (0.00% → 26.48%)
Latest values, visible window
High-resolution chart · PNG
BCLI r&d expense growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D Expense Growth |
|---|---|
| 26.4828% | |
| 121.8176% | |
| -469.6329% | |
| -19.7321% | |
| -14.1104% | |
| -24.318% | |
| 64.8804% | |
| 13.3406% | |
| 2.7871% | |
| -47.1731% | |
| -49.009% | |
| 19.184% | |
| -4.446% | |
| 19.2982% | |
| -35.09% | |
| -26.149% | |
| 95.4511% | |
| -28.855% | |
| 1.6307% | |
| 0.5279% | |
| -17.0928% | |
| -50.7823% | |
| 372.4156% | |
| -67.2111% | |
| -4.2703% | |
| -3.8474% | |
| 54.3413% | |
| 12.7743% | |
| 2.8356% | |
| -10.4663% | |
| 95.443% | |
| 33.3558% | |
| 51.5865% | |
| 162.3484% | |
| -234.161% | |
| 168.5057% | |
| -53.7726% | |
| 191.3313% | |
| -59.1139% | |
| 423.1788% | |
| -84.6856% | |
| 19.3705% | |
| -45.0432% | |
| 9.3091% | |
| 10.4418% | |
| -24.224% | |
| 4.5165% | |
| 79.2474% | |
| 28.9706% | |
| -19.9058% | |
| 5.597% | |
| 8.3558% | |
| 42.1456% | |
| 83.8028% | |
| -61.2022% | |
| 90.1299% | |
| 4.336% | |
| -43.8356% | |
| 273.2955% | |
| -69.9659% | |
| 117.037% | |
| 210.3448% | |
| -76.5499% | |
| 6.6092% | |
| 45.6067% | |
| 140.3035% | |
| -315.6364% | |
| 30.9524% | |
| -27.3356% | |
| -39.0295% | |
| 62.3288% | |
| 3.1802% | |
| -52.0339% | |
| -2.1559% | |
| 84.9693% | |
| -19.7044% | |
| -31.2339% | |
| -26.9638% | |
| 200.5115% | |
| 34.416% | |
| 2,592.8376% | |
| -102.3603% | |
| 4.8654% | |
| 70.2701% | |
| 270.2828% | |
| -99.6844% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% |